UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000056773
Receipt number R000064889
Scientific Title Anti-integrin alphaVbeta6 antibody titer and the development of ulcerative colitis: a prospective multicenter study in Japan
Date of disclosure of the study information 2025/01/23
Last modified on 2025/04/10 09:16:28

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Anti-integrin alphaVbeta6 antibody titer and the development of ulcerative colitis: a prospective multicenter study in Japan

Acronym

Anti-integrin alphaVbeta6 antibody titer and ulcerative colitis in the Japanese prospective cohort

Scientific Title

Anti-integrin alphaVbeta6 antibody titer and the development of ulcerative colitis: a prospective multicenter study in Japan

Scientific Title:Acronym

Anti-integrin alphaVbeta6 antibody titer and ulcerative colitis in the Japanese prospective cohort

Region

Japan


Condition

Condition

Ulcerative colitis

Classification by specialty

Gastroenterology

Classification by malignancy

Others

Genomic information

NO


Objectives

Narrative objectives1

This study aims to clarify the positive rate of anti-integrin alphaVbeta6 antibodies and their ability to predict the onset of ulcerative colitis in the general young Japanese population.

Basic objectives2

Others

Basic objectives -Others

N/A

Trial characteristics_1


Trial characteristics_2


Developmental phase



Assessment

Primary outcomes

Association between anti-integrin alphaVbeta6 antibody and the development of ulcerative colitis

Key secondary outcomes

-Anti-integrin alphaVbeta6 antibody positive rate
-Association between anti-integrin alphaVbeta6 antibody and ulcerative colitis prevalence


Base

Study type

Observational


Study design

Basic design


Randomization


Randomization unit


Blinding


Control


Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms


Purpose of intervention


Type of intervention


Interventions/Control_1


Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male and Female

Key inclusion criteria

Subjects who enroll in the faculties of universities or colleges related to research institutions from 2024 to 2028. The starting year for eligible students is the year in which ethics committee approval is obtained at each facility.

Key exclusion criteria

Subjects who do not consent to participate in the study.

Target sample size

6000


Research contact person

Name of lead principal investigator

1st name Tadakazu
Middle name
Last name Hisamatsu

Organization

Kyorin University School of Medicine

Division name

Department of Gastroenterology and Hepatology

Zip code

181-8611

Address

6-20-2 Shinkawa, Mitaka-shi, Tokyo

TEL

0422-47-5511

Email

thisamatsu@ks.kyorin-u.ac.jp


Public contact

Name of contact person

1st name Jun
Middle name
Last name Miyoshi

Organization

Kyorin University School of Medicine

Division name

Department of Gastroenterology and Hepatology

Zip code

181-8611

Address

6-20-2 Shinkawa, Mitaka-shi, Tokyo

TEL

0422-47-5511

Homepage URL


Email

jmiyoshi@ks.kyorin-u.ac.jp


Sponsor or person

Institute

Kyorin University School of Medicine

Institute

Department

Personal name

Tadakazu Hisamatsu


Funding Source

Organization

Self-funding

Organization

Division

Category of Funding Organization

Self funding

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Faculty of Medicine Research Ethics Committee, Kyorin University

Address

6-20-2 Shinkawa, Mitaka-shi, Tokyo

Tel

0422-47-5511

Email

rec@ks.kyorin-u.ac.jp


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions

札幌医科大学医学部消化器内科学(北海道)、東北大学医学部大学院医学系研究科消化器病態学分野(宮城県)、北里大学北里研究所病院(東京都)、杏林大学医学消化器内科学(東京都)、富山大学附属病院炎症腸疾患内科(富山県)、兵庫医科大学医学部消化器内科学講座(兵庫県)、佐賀大学医学部消化器内科(佐賀県)



Other administrative information

Date of disclosure of the study information

2025 Year 01 Month 23 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled


Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Open public recruiting

Date of protocol fixation

2024 Year 04 Month 10 Day

Date of IRB

2024 Year 05 Month 20 Day

Anticipated trial start date

2024 Year 04 Month 10 Day

Last follow-up date

2034 Year 03 Month 31 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information

Anti-integrin alphaVbeta6 antibody was reported by a Japanese study group as an autoantibody with high sensitivity and specificity for ulcerative colitis. It has also been suggested in overseas cohorts that the antibody has the potential to predict the onset of ulcerative colitis. However, the positivity rate in the general young population in Japan and the ability to predict the onset of the disease through long-term follow-up remain unclear. Since the onset of ulcerative colitis is influenced by population distribution, genetic background, and environmental factors, the ability of anti-integrin alphaVbeta6 antibodies to predict the onset of ulcerative colitis may differ in Japan from other countries. Therefore, this study aims to investigate the positive rate of anti-integrin alphaVbeta6 antibodies and their ability to predict the development of ulcerative colitis in the general young Japanese population.


Management information

Registered date

2025 Year 01 Month 21 Day

Last modified on

2025 Year 04 Month 10 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000064889